AdAlta CEO On Shark Antibody Technology
Executive Summary
AdAlta CEO Sam Cobb discusses development of the company's novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.
You may also be interested in...
Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.
Ossianix Cracks Open The Blood-Brain Barrier
By using the binding region of shark antibodies as a carrier to cross the blood-brain barrier, Ossianix reckons it has made significant progress against an issue that has held back the development of CNS-active neurological therapies.
Rising From The Ashes Of 2020: ‘We Must Not Waste The Learning,’ Says Dame Sally
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
Need a specific report? 1000+ reports available
Buy Reports